Theravance Biopharma (NASDAQ:TBPH) Issues Earnings Results

Theravance Biopharma (NASDAQ:TBPH) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25), Yahoo Finance reports. The business had revenue of $14.26 million during the quarter, compared to analyst estimates of $15.81 million. Theravance Biopharma had a negative return on equity of 18.97% and a negative net margin of 72.79%. During the same period in the prior year, the firm earned ($0.28) EPS.

Theravance Biopharma Price Performance

Shares of NASDAQ TBPH traded up $0.01 during midday trading on Wednesday, reaching $7.84. 3,533,853 shares of the company traded hands, compared to its average volume of 409,257. Theravance Biopharma has a 52 week low of $7.69 and a 52 week high of $11.71. The stock has a 50-day moving average price of $9.05 and a 200 day moving average price of $9.09. The company has a market cap of $381.28 million, a price-to-earnings ratio of -9.22 and a beta of 0.24.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. BTIG Research assumed coverage on shares of Theravance Biopharma in a report on Friday, April 12th. They issued a “buy” rating and a $21.00 price objective for the company. TD Cowen decreased their price objective on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a report on Tuesday. SVB Leerink cut Theravance Biopharma from an “outperform” rating to a “market perform” rating and cut their target price for the company from $15.00 to $10.00 in a research note on Tuesday. StockNews.com cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, HC Wainwright cut their target price on Theravance Biopharma from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $13.75.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 335,965 shares in the company, valued at $3,023,685. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 6.90% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.